CKM syndrome reflects the fact that metabolic dysfunction, chronic kidney disease, and cardiovascular disease share several biological pathways and frequently progress together rather than as isolated conditions. This overlap means that a single patient may carry elements of type 2 diabetes, obesity, chronic kidney disease, heart failure, and atherosclerotic cardiovascular disease at the same time. The review frames this shared biology as the rationale for therapies that act on mechanisms common to all three domains rather than on one organ in isolation.

According to the authors, several established drug classes have shown cardiovascular, kidney, and metabolic benefits across multiple high-risk populations. These include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, and lipid-lowering therapies. Because each class acts on pathways that recur throughout the CKM spectrum, the review positions them as the mechanistic backbone of current treatment, with benefits documented in trials involving patients with diabetes, kidney disease, heart failure, obesity, and atherosclerotic cardiovascular disease.

A key limitation the review identifies is that most of this evidence comes from trials that enrolled patients with individual conditions rather than populations defined by CKM stage or phenotype. The trials that established the benefits of SGLT2 inhibitors, GLP-1 receptor agonists, and the other backbone therapies were designed around single diagnoses, so their results cannot automatically be assumed to apply to patients whose disease spans the full CKM spectrum. This mismatch between trial populations and the integrated CKM framework is one of the central evidence gaps the authors highlight.

The review also notes that evidence for the added clinical benefit of specific treatment combinations remains limited. While the mechanistic logic of pairing therapies that act on complementary pathways is strong, the authors emphasize that the clinical trial base for combination strategies in CKM syndrome has not caught up with that logic. Clinicians considering multi-drug regimens for patients with overlapping cardiovascular, kidney, and metabolic disease therefore have less direct trial evidence to draw on than clinicians treating any single condition within the syndrome.

Looking ahead, the review describes newer therapies that may broaden the treatment options available for CKM syndrome. These include agents targeting aldosterone synthesis, endothelin signaling, inflammation, incretin pathways, and lipid-related pathways. Each target corresponds to a biological mechanism implicated in the progression of cardiovascular, kidney, and metabolic disease, and the authors present them as candidates that could extend the mechanism-based approach beyond the currently established drug classes.

For clinical practice, the authors propose that CKM stage and the predominant clinical phenotype may help identify treatment priorities for individual patients. This phenotype-directed approach would account for coexisting conditions, safety considerations, treatment burden, cost, and access, factors the review identifies as practical constraints on therapy selection. By matching the mechanism of a given therapy to the dominant clinical picture of a patient, the framework aims to provide a rational basis for choosing among the growing number of options across the CKM spectrum.

The authors are careful to distinguish this practical framework from a proven clinical strategy. They state that the phenotype-directed approach may provide a basis for selecting therapies, but that prospective studies are needed to determine whether it improves clinical outcomes. Until such studies are completed, the review’s contribution lies in organizing the existing mechanistic and trial evidence around the CKM framework rather than in establishing new treatment standards.

Taken together, the review offers a synthesis of where mechanism-based therapy in CKM syndrome stands today: a set of drug classes with benefits demonstrated in single-condition trials, an emerging pipeline of agents aimed at shared biological pathways, and a proposed staging and phenotype framework for applying both in practice. The gap between that framework and validated outcome evidence is the question the authors leave for future prospective research.

Subject of Research: Mechanism-based therapeutic strategies for cardiovascular-kidney-metabolic syndrome

Article Title: Mechanism-based therapeutic strategies in cardiovascular-kidney-metabolic syndrome: integrating biological pathways with evidence from clinical trials

Article References: Nzobokela, J., Choolwe, S. C., & Masenga, S. K. (2026). Mechanism-based therapeutic strategies in cardiovascular-kidney-metabolic syndrome: integrating biological pathways with evidence from clinical trials. Frontiers in Endocrinology, 17, Article 1987811. https://doi.org/10.3389/fendo.2026.1987811

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1987811

Keywords: cardiovascular-kidney-metabolic syndrome, SGLT2 inhibitors, GLP-1 receptor agonists, combination therapy, mechanism-based therapy, chronic kidney disease, clinical trials, phenotype-directed treatment, mineralocorticoid receptor antagonists, renin-angiotensin system inhibitors, lipid-lowering therapies, Mechanism-based